Dergiler / Şişli Etfal Hastanesi Tıp Bülteni / 2019 / Cilt: 53 - Sayı: 2

Is Cardiac Troponin I Valuable to Detect Low-Level Myocardial Damage in Congestive Heart Failure?

Sayfa
172–178
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This increase was inversely related to the EF value.These results are consistent with other studies in the literature, suggesting that the cTnI level may be a useful marker in the diagnosis and evaluation of severity of HF.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Congestive heart failure (CHF) is a heart disease with a growing incidence and prevalence.
📊
Temel Bulgular & Veri:Theaim of this study was to ascertain whether cardiac troponin I (cTnI) can be used to detect low-level myocardial damage occurringin CHF in real-life conditions.Methods: Fifty patients with CHF symptoms (Group I) and 20 patients who were evaluated as normal (Group II) were included inthis prospective study.
💡
Sonuç & Katkı:This increase was inversely related to the EF value.These results are consistent with other studies in the literature, suggesting that the cTnI level may be a useful marker in the diagnosis and evaluation of severity of HF.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: Congestive heart failure (CHF) is a heart disease with a growing incidence and prevalence. Creatine kinase-myocardialbase (CK-MB) is generally used to determine myocardial damage; however, it is insufficiently sensitive to measure the relatively lowlevel of myocardial damage that typically occurs in heart failure (HF). The use of cardiac troponins, which are far more sensitive andspecific, has become common to identify myocardial damage and permits the detection of even minute amounts of damage. Theaim of this study was to ascertain whether cardiac troponin I (cTnI) can be used to detect low-level myocardial damage occurringin CHF in real-life conditions.Methods: Fifty patients with CHF symptoms (Group I) and 20 patients who were evaluated as normal (Group II) were included inthis prospective study. The Framingham criteria were used to diagnose HF. Group I was divided into 3 subgroups according to theNew York Heart Association classification of functional capacity: Class II, Group A; Class III, Group B, and Class IV, Group C. On thefirst day of admission, CK-MB and cTnI levels were measured and assessed quantitatively. The cTnI level was compared betweenthese 3 subgroups and between Groups I and II. Linear regression analysis was performed to investigate the relationship betweenejection fraction (EF) and cTnI.Results: The mean cTnI value was 0.084±0.07 ng/mL in Group I and 0.018±0.012 ng/mL in Group II (p=0.0001). The mean cTnI valuewas 0.047±0.016 ng/mL, 0.080±0.048 ng/mL, and 0.175± 0.102 ng/mL in Groups A, B, and C, respectively. The difference betweenthe subgroups of Group I was statistically significant. In addition, it was observed that there was a significant difference in the EF(%) value between Groups I and II and between Groups A, B, and C. Linear regression analysis revealed an inverse relationship between EF and cTnI (r: -0.66) (p=0.0001).Conclusion: As the severity of HF increased, the cTnI serum level also increased. This increase was inversely related to the EF value.These results are consistent with other studies in the literature, suggesting that the cTnI level may be a useful marker in the diagnosis and evaluation of severity of HF.

🔖

Bu Makaleye Atıf Yap

ŞİRİN, G., BORLU, F. (2019). Is Cardiac Troponin I Valuable to Detect Low-Level Myocardial Damage in Congestive Heart Failure?. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 53 - Sayı: 2, 172–178. https://ajindex.com/articles/363442

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. JACC 2013;62:147–239. 2. de Tombe PP. Altered contractile function in heart failure. Cardiovasc Res 1998;37:367–80
  2. Weil J, Eschenhagen T, Magnussen O, Mittmann C, Orthey E, Scholz H, et al. Reduction of myocardial myoglobin in bovine dilated cardiomyopathy. J Mol Cell Cardiol 1997;29:743–51
  3. Ricchiuti V, Zhang J, Apple FS. Cardiac troponin I and T alterations in hearts with severe left ventricular remodeling. Clin Chem 1997;43:990–5
  4. Polanczyk CA, Lee TH, Cook EF, Walls R, Wybenga D, Printy-Klein G, et al. Cardiac troponin I as a predictor of major cardiac events in emergency department patients with acute chest pain. J Am Coll Cardiol 1998;32:8–14
  5. Haller C, Zehelein J, Remppis A, Müller-Bardorff M, Katus HA. Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. Clin Chem 1998;44:930–8
  6. Sparano JA, Wolff AC, Brown D. Troponins for predicting cardiotoxicity from cancer therapy. Lancet 2000;356:1947–8
  7. Ricchiuti V, Voss EM, Ney A, Odland M, Anderson PA, Apple FS. Cardiac troponin T isoforms expressed in renal diseased skeletal musclewill not cause false-positive results by the second generation cardiactroponin T assay by Boehringer Mannheim. Clin Chem 1998;44:1919–24
  8. Sheehan P, Vasikaran SD. The evolving clinical role of cardiac troponins and new acute myocardial infarction guidelines: implications for the clinical laboratory. Clin Bichemist Rev 2001;23:52–65
  9. Wu AH. Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? Intensive Care Med 2001;27:959–61
  10. Jaffe AS. 2001--a biomarker odyssey. Clin Chim Acta 1999;284:197– 211
  11. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiactroponin T. Am Heart J 1999;138:95–9
  12. La Vecchia L, Mezzena G, Ometto R, Finocchi G, Bedogni F, Soffiati G,et al. Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol 1997;80:88–90
  13. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703–12
  14. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nat